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INTRODUCTION

Glioblastoma (GBM) is an aggressive primary tumor of the central
nervous system (CNS) that is lethal despite the continuous efforts to
treat the disease (1, 2). While immunotherapy has become immensely
effective for most malignancies, for brain tumors it remains disappointing, in part, because of the immune composition of brain
tumors (3). GBM has an infiltration of tumor-associated myeloid
cells (TAMCs) and deficiency of T cells that is more robust than any
other tumor measured (4). TAMCs are a key driver of immunosuppression and thus a barrier to successful immunotherapy for glioma
(5, 6). Recently, there have been large-scale “omics” approaches to
understand the immunological composition of glioma and how they
influence patient survival (4, 7, 8). These studies have highlighted the
importance of myeloid infiltration in glioma and identified targeting
of the myeloid compartment as a therapeutic strategy for glioma. For
example, we have recently used a TAMC-targeting system that works
synergistically with irradiation and chemotherapy to promote survival
in multiple animal models of the disease (9). Other groups have also
used other TAMC-targeting approaches/therapies to influence the
myeloid compartment of brain tumors (10, 11). Moreover, recent
studies indicate that modulating metabolic pathways can affect
tumor immunity (12–14).
Brain tumors exist in a harsh environment consisting of severe
hypoxia (15), extracellular acidification (16–18), and nutrient competition (19, 20). Hypoxia and acidity enhance both cancer aggres1
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siveness (21) and immunosuppression (22, 23). Extracellular acidity
(pHe) causes several immunosuppressive aspects of tumor biology.
pHe enforces T cell unresponsiveness, and its blockade can promote
checkpoint immunotherapy for melanoma (24, 25). Furthermore,
recent work highlighted that pHe can directly enforce the immunosuppressive phenotype of macrophages (26). How TAMCs survive
the acidic tumor microenvironment (TME) is not fully understood
and is addressed in this study.
RESULTS

TAMCs catabolize arginine to polyamines in brain tumors
To gain insight into this phenomenon, we implanted 7.5 × 104 CT-2A
glioma cells intracranially into C57/Bl6 mice. After 2 weeks of tumor
growth, TAMCs were isolated and compared to splenic myeloid cells
using bulk metabolite analysis by liquid chromatography–tandem
mass spectrometry (LC-MS/MS; Fig. 1A) and RNA-sequencing
(RNA-seq) analysis (Fig. 1B). Using a Gr1-based isolation, we
achieved a high purity (≥89%) of TAMCs from the brain and myeloid
cells from the spleen (fig. S1, A and B) for our downstream analysis.
Note that the flow cytometric phenotypes of splenic myeloid cells
do not significantly differ from those isolated from the blood in regard
to arginase, PD-L1, and percent Ly6C positivity of the CD45+CD11b+
population (fig. S1, C and D). For these reasons, we used splenic
myeloid cells as a surrogate for probing peripheral myeloid metabolism. Unbiased examination of bulk metabolites revealed that TAMCs
have a significant decrease in arginine with a concomitant increase
in its downstream metabolites, ornithine, putrescine, and spermidine (Fig. 1A and table S1). Supporting this observation, we found
that enzymes responsible for the catabolism of arginine into ornithine
are significantly up-regulated in TAMCs (Tumor Gr1) compared to
peripheral myeloid cells (Spleen Gr1) (Fig. 1B). Expression of other well-
established myeloid-derived suppressor cells (MDSCs)/tumor-associated
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Glioblastoma is characterized by the robust infiltration of immunosuppressive tumor-associated myeloid cells (TAMCs).
It is not fully understood how TAMCs survive in the acidic tumor microenvironment to cause immunosuppression
in glioblastoma. Metabolic and RNA-seq analysis of TAMCs revealed that the arginine-ornithine-polyamine axis is
up-regulated in glioblastoma TAMCs but not in tumor-infiltrating CD8+ T cells. Active de novo synthesis of highly
basic polyamines within TAMCs efficiently buffered low intracellular pH to support the survival of these immunosuppressive cells in the harsh acidic environment of solid tumors. Administration of difluoromethylornithine
(DFMO), a clinically approved inhibitor of polyamine generation, enhanced animal survival in immunocompetent
mice by causing a tumor-specific reduction of polyamines and decreased intracellular pH in TAMCs. DFMO combination with immunotherapy or radiotherapy further enhanced animal survival. These findings indicate that polyamines are used by glioblastoma TAMCs to maintain normal intracellular pH and cell survival and thus promote
immunosuppression during tumor evolution.
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Fig. 1. TAMCs up-regulate the arginine-polyamine axis in brain tumors. (A to C) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 14 days of tumor
engraftment, myeloid cells from the brain (TAMCs) and spleen were isolated via Gr1 magnetic bead isolation and analyzed via LC-MS/MS for metabolomics (A) (table S1)
and RNA-seq (B). (A) Normalized peak areas of samples were graphed in MetaboAnalyst (74). RNA-seq data were visualized using GSEA heatmap analysis for arginine
metabolic genes (B). (C) Left: Fpkm values comparing hallmark arginine metabolite genes. Right: Metabolite levels in TAMCs versus peripheral myeloid cells. (D) Flow
cytometric expression of arginase-1 in matched peripheral versus tumor myeloid cells of both humans and mice. (E) Schematic of the arginine metabolic pathway. (F) In
vitro generated CD8+ T cells and TAMCs were cultured in 13C-arginine SILAC medium for 2 hours before LC-MS/MS. (G) TAMC and CD8+ T cells were isolated from
tumor-bearing mice and pulsed ex vivo with 13C-arginine for 2 hours [4 hours in (H)] and analyzed via LC-MS/MS. (A and B) Each replicate is n = 10 mice pooled per sample,
three independent experiments (a total of n = 30 mice). (C) Five matched human and four matched mouse samples were analyzed for arginase-1 expression. (D) n = 4
matched human samples were analyzed for bulk metabolite analysis. Significance was calculated by Student’s t test: **P < 0.01 and ***P < 0.001.
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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Polyamines promote myeloid-driven immunosuppression
Considering that TAMCs have a preference for generating putrescine
from arginine, we analyzed the levels of polyamines in TAMCs compared to CD8+ T cells in Fig. 2A. The normalized peak area levels of
polyamines, particularly putrescine, were greater than fourfold
up-regulated in TAMCs (2.2 × 106 ± 1.8 × 105) versus spleens
(5.6 × 105 ± 1.9 × 105; P < 0.001). Similarly, spermidine levels were
3.82-fold up-regulated in TAMCs (1.02 × 108 ± 6.4 × 106) versus
spleens (2.7 × 107 ± 2.5 × 106; P < 0.001). In CD8+ T cells, there was
a trend toward a decrease of putrescine in tumors (P = 0.1), with
an increase in spermidine levels in tumors (0.12-fold increase;
P < 0.05). The role of polyamines in myeloid immunosuppression
has been addressed previously, as Yu et al. (29) have revealed that
blockade of de novo polyamine generation using difluoromethylornithine (DFMO) inhibits MDSC-mediated suppression of T cells. To
determine whether the polyamine pathway is required for immunosuppression, we generated TAMCs as previously described (9) and
performed CD8+ T cell suppressor assays with polyclonal T cells in
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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Fig. 2B. At 1:2 and 1:4 TAMC:CD8+ T cells ratios, DFMO pretreatment
(added immediately upon differentiation at day 0) caused a significant
decrease in TAMC suppressor functions. LC-MS/MS analysis revealed
that DFMO pretreatment depletes both putrescine and spermidine
from TAMCs (fig. S3A). To determine whether this can influence
antigen-specific responses, we performed the same assay using
OT-1 CD8+ T cells and SIINFEKL peptide stimulation for 48 hours
in Fig. 2C. Similar to polyclonal cultures, DFMO pretreatment
markedly impaired TAMC-induced suppression.
To determine whether DFMO can block polyamine generation
in vivo, we implanted mice with CT-2A and, after 5 days of tumor
engraftment (which was sufficient time for tumor establishment as
verified by neuropathological examination), administered 1% DFMO
in their drinking water ad libitum. After 7 days of water treatment,
TAMCs were isolated and compared to splenic myeloid cells using
LC-MS/MS (Fig. 2D). While splenic myeloid cells showed no changes
in polyamine content, TAMCs had significant reductions in their
polyamine content. This suggests that de novo polyamine generation is required only within the TME. To understand whether this
reduction is specific to the arginine-ornithine-polyamine axis, we
performed a 4-hour 13C-arginine relative isotopic incorporation
ex vivo (Fig. 2E). While there was no difference in the amount of
13
C-labeled ornithine in DFMO-treated animals (suggesting that
M+5 ornithine incorporation is at steady state), the amount of
labeled putrescine was almost entirely diminished in the TAMCs of
DFMO-treated mice (P < 0.001; Fig. 2E). There was no change in
13
C-labeled putrescine in peripheral myeloid cells, supporting a
tumor-specific phenomenon. To address the possibility of steadystate labeling, we performed a 13C-arginine metabolite flux analysis
over multiple time points and found that ornithine flux was reduced
in DFMO-treated animals at 1 hour (P < 0.001), while it remained
steady after 2 hours (fig. S3B). Putrescine labeling occurred beginning
at 4 hours of flux in which DFMO-treated animals never had putrescine labeling (fig. S3C). These facts suggest that DFMO treatment
stymies arginase activity, while it abolishes ODC1 activity. There was
no change in 13C-labeled urea cycle metabolites, confirming the RNAseq and bulk metabolomics data (fig. S4). This suggests that the urea
cycle/iNOS pathway is inactive in TAMCs in glioma.
We also analyzed the bulk metabolites that significantly changed
by DFMO treatment in TAMCs (fig. S5) to determine other effects
of polyamine inhibition. We found a broad array of metabolites
down-regulated by DFMO treatment that was independent of arginine
metabolism, such as N-acetylglucosamine, guanosine diphosphate,
and glutamine (fig. S5A). Some metabolites were increased by DFMO
treatment, such as 2,3-bisphosphoglycerate, deoxyguanosine, pantothenic acid, and others (fig. S5B). This suggests that polyamine
inhibition exerts effects beyond just the arginine metabolic pathway.
Polyamine blockade enhances antitumor immunity in GBM
We next sought to understand whether DFMO can be used to promote animal survival in our murine models of glioma. After 5 days
of tumor establishment, mice with ad libitum access to 1% DFMO
drinking water showed a significant enhancement in survival (median
survival of 20 days in controls versus 33 days in DFMO treatment;
P < 0.001), as indicated in Fig. 3A. Considering that ODC1 is broadly
expressed in most brain tumors and inversely correlated with patient
survival (fig. S6), there is a possibility that inhibition of ODC1 may
directly influence the growth of tumor, rather than antitumor
immunity (30). To rule out this possibility, we performed the same
3 of 15
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macrophage (TAM) markers, such as CCR2, PD-L1, and transforming growth factor– (TGF-), was also enriched in TAMCs,
highlighting the validity of this approach (fig. S2A). GSEA (Gene
Set Enrichment Analysis) plots generated from RNA-seq data revealed other metabolic pathways up-regulated in TAMCs such as
fructose, mannose, and galactose metabolism (fig. S2B). There were
also other metabolic pathways down-regulated in the tumor such as
nitrogen, glutathione, arachidonic, and purine metabolism (fig. S2C).
Statistical analysis revealed that TAMCs exhibit a 3.27-fold increase in ornithine compared to splenic myeloid cells. There was a
concomitant decrease in intracellular arginine levels, indicating
robust arginine catabolism (Fig. 1C). Flow cytometric analysis confirmed the up-regulation of arginase-1 in both mouse and human
TAMCs compared to peripheral myeloid cells (Fig. 1D). This is consistent with previous studies of arginase-1 expression in TAMCs in
glioma (27, 28). We found minimal evidence of critical urea cycle
enzymes ornithine transcarbamylase (OTC) and carbamoyl phosphate
synthetase 1 (CPS1) or their metabolites (citrulline and carbamoyl
phosphate, respectively) in TAMCs or splenic myeloid cells (fig. S2D).
To validate these observations and to understand whether they
are myeloid-specific, we first generated TAMCs (9) and CD8+ T cells
in vitro and performed a 2-hour 13C-arginine relative isotopic incorporation. The M+5 incorporation of TAMCs was 76.5 ± 1.2%
compared to 20.9 ± 0.9% for CD8+ T cells (Fig. 1F), highlighting the
preferential flux of arginine into ornithine by TAMCs. To confirm
that this phenomenon occurs similarly in vivo, we performed magnetic
bead isolation of TAMCs (Gr1) and CD8+ T cells (CD8) from CT-2A
glioma–bearing mice and performed the same ex vivo 13C-arginine
relative isotopic incorporation (Fig. 1G). Again, the results show
that M+5 incorporation of TAMCs was 69.4 ± 3.2% compared to
3.4 ± 3.4% for CD8+ T cells. These data may suggest that ornithine
generation is critical to TAMCs in GBM. Considering that the urea
cycle and inducible nitric oxide synthase (iNOS) activity does not
appear to be occurring in TAMCs, the only other fate of ornithine is
its catabolism to polyamines. The rate-limiting enzyme in this pathway
is ornithine decarboxylase 1 (ODC1), which was highly up-regulated
in TAMCs (Fig. 1C). A 4-hour ex vivo 13C-arginine relative isotopic
incorporation revealed that TAMCs robustly generated putrescine
from arginine, whereas peripheral myeloid cells showed limited capability (39.5 ± 0.9% versus 9.4 ± 3.4%, respectively) (Fig. 1H).
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Fig. 2. Polyamines accumulate in TAMCs in GBM and can be efficiently depleted in vivo. (A) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 14 days
of tumor engraftment, TAMCs were isolated via Gr1 magnetic bead isolation and CD8+ T cells were isolated via CD8+ magnetic bead isolation. (B) In vitro generated
TAMCs pretreated with DFMO before being cocultured with decreasing ratios of splenic CD8+ T cells labeled with CellTrace Violet dye. (C) The same assay was performed
using OT-1 T cells stimulated with SIINFEKL peptide. Forty-eight (C) and 72 (B) hours after coculture, T cell proliferation was analyzed via flow cytometric analysis. (D and
E) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 5 to 6 days of tumor engraftment, 1% DFMO water was supplied ad libitum to experimental mice. After
7 days of DFMO water treatment, TAMCs were magnetically isolated for bulk metabolomics (D) or pulsed in vitro with 13C-arginine for 4 hours before metabolite isolation
(E). (F) Schematic overview of polyamine metabolism. (A, D, and E) Each sample is n = 8 to 10 mice pooled per sample, three pooled samples per group. (B and C) Suppressor
assays were carried out with n = 3 per each ratio tested, representative of two independent experiments. All statistics in this figure were analyzed by unpaired Student’s
t tests: *P < 0.05, **P < 0.01, and ***P < 0.001; ns, not significant. All LC/MS data were normalized to total ion count (TIC). i.c., intracranial.
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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To understand whether DFMO can be used to potentiate immunotherapy, we administered anti–PD-L1 therapeutic antibody together
with DFMO treatment in mice and found an additive effect on animal survival (median survival of 26 days in anti–PD-L1 treatment,
30 days in DFMO treatment, and 45 days in the combination group;
P < 0.001) (Fig. 4C). Combinatorial therapy using anti–PD-1 also
increased animal survival (Fig. 4D). As previous work has shown
that polyamines can protect GBM from the antitumor effects of
radiotherapy (32), we also treated mice with DFMO and radiotherapy
(3 Gy × 3 days), which also resulted in combinatorial survival benefit in mice (Fig. 4E). As the CT-2A model is normally resistant to
checkpoint blockade, these data highlight the importance of myeloid
cells in promoting the efficacy of both checkpoint immunotherapy
and radiotherapy. To examine the immunological effects of combinatorial therapy, we implanted mice with GL-261 tumors overexpressing ovalbumin (OVA) and followed up with treatment of anti–
PD-L1, DFMO, or combination starting at 1 week after implantation.
One week after therapeutic administration, using tetramer staining,
we found an increase in OVA-specific T cells within the tumors of
combinatorial-treated animals (P < 0.05; Fig. 4, F and G). This suggests that DFMO and checkpoint administration promotes antigen-
specific T cell recruitment to brain tumors.
Polyamines buffer the intracellular pH of TAMCs
We next sought a mechanistic understanding as to why TAMCs have
a preference for generation of polyamines in brain tumors. We
explored the possibility that as polyamines are highly basic compounds (33), perhaps they are playing a role in TAMC survival in
the acidic and hypoxic glioma microenvironment. To determine
whether this brain tumor model has an acidic environment, we implanted mice with CT-2A tumors and, 14 days after engraftment,
injected mice intravenously with the extracellular pH-sensing probe
pHLIP (pH-low insertion peptide) labeled with fluorescent dye
Cy5.5 (pHLIP-Cy5.5) and compared to mice without tumors (Fig. 5A).
The pHLIP probe only inserts into the membrane of cells within
acidic extracellular environments, while it will wash out of pH neutral
tissues (34). IVIS imaging demonstrated a strong signal only within
tumor-bearing brains but minimal detection in nontumor brains
(2.03 × 107 ± 8.14 × 106 versus 1.3 × 106 ± 2.22 × 105 maximum
radiance in tumors compared to controls, respectively; P < 0.001) or
spleens. This shows that brain tumors generate an extracellular
acidic milieu.
We next determined whether polyamines endow TAMCs the ability
to survive under conditions of pHe (Fig. 5, B and C). To test this
hypothesis, we generated TAMCs in vitro and then cultured for additional 48 hours under pH 6.7 condition. Unexpectedly, DFMO
pretreatment caused significant necrosis of TAMCs in the context
of acidity but not controls (21.1 ± 1.62% versus 2.2 ± 0.36%, respectively; P < 0.001). To highlight that polyamines are critical for
preventing intracellular acidity–induced cell death, we added putrescine back to our TAMC cultures during DFMO treatment, which
was able to rescue TAMC cell death under conditions of pHe. To
observe this phenomenon in vivo, we treated mice with DFMO and
performed flow cytometry using the pH-sensitive dye pHrodo to
measure intracellular pH in TAMCs. pHrodo Red AM dye is taken
by cells and activated by low pH, of which the fluorescence intensity increases along with the decreased pH (35). Measurement of
normalized pHrodo revealed a significant increase of fluorescence
in TAMCs of tumor-bearing mice treated with DFMO that did not
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survival experiment in RAG-1 knockout (KO) mice (lacking T and
B cells) and found a minimal change in the survival of mice (median
survival of 16 days in controls versus 19 days in DFMO treatment;
P < 0.001) (Fig. 3B). This strongly supports the hypothesis that
DFMO perturbs the immunosuppressive microenvironment of glioma,
not glioma cells themselves. Flow cytometric analysis demonstrated
that the myeloid compartment (including microglia) in the tumor
of DFMO-treated RAG-1 KO mice significantly up-regulates tumor
necrosis factor– (TNF; fig. S7A), while other cytokines were unaffected. Notably, after 1 week of DFMO treatment in immunocompetent animals, a significant reduction in the myeloid:CD8+
T cell ratio was observed as shown in Fig. 3C. Consistent with our
metabolic data, DFMO appears to specifically target M-MDSCs
(monocytic MDSCs)/monocytes, microglia, and TAMs in the tumor,
as PMN-MDSCs (polymorphonuclear MDSCs)/neutrophils and all
measured T cell subsets were unaffected (Fig. 3D). DFMO treatment
caused a significant reduction in arginase-1 expression within the
M-MDSC/monocyte compartment, suggesting that DFMO causes
perturbation of the entire arginine metabolic pathway (Fig. 3C).
The gating strategy of this analysis can be found in fig. S8 (A and B).
To validate the flow cytometric data, immunofluorescence was performed on tumor tissues harvested from control and DFMO-treated
mice (Fig. 3, E and F). Our data, again, show a significant decrease
in CD11b+ cells (P < 0.04) and CD11b/CD8 ratio (8.1 ± 0.7 in controls compared to 2.4 ± 0.3 in DFMO-treated brains; P < 0.001) in
the tumor with a concomitant increase in CD8+ cells (19 ± 2 cells
per 20× field in controls compared to 49 ± 4.6 in DFMO-treated
brains; P < 0.001).
DFMO administration in another syngeneic model of glioma
(GL-261) also revealed a significant improvement in animal survival
(fig. S9A). In this model, we observed a survival benefit (median
survival of 20 days in control and 24 days in DFMO treatment;
P < 0.05; fig. S9A), a reduction of TAMC/T cell ratios (P < 0.07;
fig. S9B), a down-regulated arginase expression (P < 0.01; fig. S9C),
and a lower abundance of M-MDSC/monocytes (P < 0.05; fig. S9E)
with DFMO administration. Marked differences were observed between the two models. In GL-261 model, there were significant increases in CD8/CD4 ratio with DFMO administration (0.8 ± 0.05 in
controls compared to 1.3 ± 0.14 in DFMO-treated brains; P < 0.01;
fig. S9D), while we did not observe differences in microglial populations (fig. S9E). This suggests that there might be a model-to-model
variation in the way polyamine blockade influences anti-GBM
immunity; TAMC perturbation is a common effect.
Polyamines are ubiquitous in nature and have been ascribed to
many roles in cells. A seminal study shows that polyamines are required for the proliferation of all mammalian cells (31). To this end,
we sought to determine whether TAMCs are generating polyamine
to fuel their intratumoral proliferation (Fig. 3G). While there was
no change in the Ki-67 expression in TAMCs, Ki-67 was significantly
up-regulated in T cell subsets measured in the brain of DFMO-treated
mice (P < 0.05). However, there was no change in cytokine expression in T cells of DFMO-treated animals, suggesting that other mechanisms of immunosuppression were still functional in these mice
(fig. S8, C and D). We observed that although pretreatment with
DFMO decreased TAMC/T cell ratios in vivo, it largely up-regulated
the expression of PD-L1 on TAMCs in vivo (Fig. 4A) and in vitro
(Fig. 4B). Supplementation of TAMCs with exogenous putrescine
was able to rescue this up-regulation. This suggests that checkpoint
molecules are still functioning in the context of DFMO treatment.
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Fig. 3. Polyamine depletion promotes T cell–driven antitumor immunity in GBM. C57/Bl6 (A) or RAG10/0 (B) mice were implanted with 7.5 × 104 CT-2A tumor cells,
and after 5 to 6 days of tumor engraftment, 1% DFMO water was given. Animal survival was then measured and graphed. (C and D) Mice were implanted with 7.5 × 104
CT-2A, administered DFMO ad libitum at day 5, and analyzed via flow cytometry 5 days after DFMO treatment. (C) Ratio of myeloid to T cells; monocyte expression
of arginase-1 was calculated. (D) Absolute numbers of myeloid and T cell subpopulations in CT-2A tumor–bearing animals with or without DFMO administration.
(E and F) Brains from controls or mice treated with DFMO were harvested and flash-frozen before immunofluorescence was performed using CD11b–Alexa Fluor 488 and
CD8-PE. (G) Ki-67 expression of all major immune subsets in the tumor compared to the spleen of tumor-bearing mice treated with 1% DFMO in their drinking water
as in (C) and (D). (A and B) n = 10 mice per group were used (5 male and 5 female per group, all age-matched at 6 to 8 weeks of age), representative of four experiments
in (A) and two experiments in (B). (C, D, and G) n = 4 to 5 mice per group were analyzed and are representative of two independent experiments for each panel. (F) n = 4
mice per group were blindly counted for cellular infiltration. (A and B) Significance was calculated using log-rank analysis followed by Bonferroni correction. (C, D, F,
and G) Statistics were calculated via unpaired Student’s t test: *P < 0.05, **P < 0.01, and ***P < 0.001. DAPI, 4′,6-diamidino-2-phenylindole; Tconv, conventional T cell; Treg,
regulatory T cell.
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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occur in the spleen (Fig. 5D). Accordingly, the mean fluorescence
intensity (MFI) of pHrodo was significantly increased in TAMCs of
DFMO-treated mice (1788 ± 157 arbitrary units in control versus
2179 ± 53 DFMO treated; P < 0.05) (fig. S9F), indicating that polyamines are generated within TAMCs to maintain normal intracellular
pH and promote survival within the acidic TME. We further validated these findings by generating TAMCs in vitro under DFMO
or DFMO + putrescine supplementation, labeled them with
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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pHrodo, and monitored fluorescence change under acidic pHs
over time using the IncuCyte imaging platform (Fig. 5, E and F).
Comparison of treatments across lowering pH revealed that DFMO
significantly promotes intracellular acidity in TAMCs that is rescued by putrescine pretreatment (Fig. 5F). Thus, TAMCs treated
with DFMO are unable to maintain a neutral intracellular pH under
acid stress, whereas controls and putrescine rescue could better handle
acid stress. Excessive acidification hinders glycolytic metabolism.
7 of 15
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Fig. 4. Polyamine inhibition promotes multiple different therapies for GBM. (A) Mice were implanted with 7.5 × 104 CT-2A, pretreated with DFMO, and analyzed for
PD-L1 MFI expression. (B) TAMCs were generated in vitro in the context of DFMO or DFMO + putrescine, and PD-L1 expression was analyzed after 7 days of differentiation.
(C) The same DFMO schema was used in combination with anti–PD-L1 treatment (or treated with monoclonal antibody alone), and animal survival was measured.
(D) Seven days after tumor implantation, mice were treated with anti–PD-1 (every 3 days, 10 mg/kg) or combination therapy, and survival was analyzed. (E) Seven days
after tumor implantation, mice were treated with DFMO, 3 × 3-Gy irradiation (IR), or combination. (F and G) GL-261 (2 × 105) overexpressing OVA were implanted intracranially into mice that were then treated with PD-L1, DFMO, or combinatorial treatment. Brains were harvested and stained for tetramer positivity. (A and B) Data are n = 3
per group representative of two independent experiments. Survival curves were performed n = 8 (C) and n = 10 (D and E) mice per group. Five male and five female mice
per group were analyzed in (D) and (E); n = 4 per gender in (C), all age-matched at 6 to 8 weeks of age. (F and G) n = 5 per group were analyzed. Significance in (C) to (E)
was calculated using log-rank analysis followed by Bonferroni correction. Significance in (A) and (B) and (F) and (G) was calculated by one-way analysis of variance (ANOVA),
followed with a Tukey’s post hoc test: *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 5. Polyamines promote the metabolism and survival of TAMCs by regulating acidic stress produced by the tumor microenvironment. (A) Mice were implanted with tumors or phosphate-buffered saline (PBS) and, after 14 days, injected with 100 M pHLIP-Cy5.5 dye via intravenous injection. Twenty-four hours after injection,
brains and spleen were quantified using a spectral imaging system. (B and C) TAMCs were generated in the context of DFMO or in DFMO with exogenous putrescine.
After 6 days of differentiation, cells were lifted and replated into complete RPMI buffered to an acidic pH. Forty-eight hours after replating, flow cytometric analysis was
performed to determine apoptosis/necrosis of TAMCs. (D) Spleens and tumor-infiltrating lymphocytes from controls or DFMO-treated animals were stained with pHrodo
Red AM intracellular pH dye. (E) Intracellular pH was determined by generation of pH standard curve. RCU, red calibrated unit. (F) TAMCs were generated under control
conditions and pretreated with DFMO or DFMO + 100 M putrescine added. After 6 days, cells were washed and labeled with pHrodo Red AM dye. IncuCyte analysis was
then performed to monitor intracellular acidity over time. After 2 hours of measurement, nigericin/valinomycin was added. n = 4 wells per group, representative of three
independent experiments. (A) n = 4 control and tumor-bearing brains/spleens were analyzed. (B to D) n = 3 per group, representative of two independent experiments.
Significance was calculated via unpaired Student’s t tests (A and D) and one-way ANOVA with Tukey’s post hoc for individual comparisons in (C) and (F):
*P < 0.05, **P < 0.01, and ***P < 0.001.
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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DISCUSSION

Arginase-1 expression has been considered a hallmark of the suppressive myeloid phenotype for the past 20 years (43, 44). Alongside
these observations, many studies have shown that the catabolism of
the argainse-1 metabolite, ornithine (via ODC1), broadly promotes
the immunosuppression of myeloid lineage cells (29, 45, 46).
Supporting the importance of polyamine generation in myeloid
function, a recent critical study revealed that macrophages generate
polyamines to support the alternative activation of macrophages via
the hypusination of EIF5 (47). While there is abundant evidence
that this pathway is important for myeloid cell to induce immunosuppression, the mechanism why this metabolic pathway is invoked
has yet to be understood. Our results provide a potential metabolic
explanation whereby the generation of the polyamine putrescine acts
as pH buffer against hostile acidic TME to promote both the survival
and metabolic functions of TAMCs in GBM.
Immunosuppressive or “inflammation-resolving” myeloid cells
must enter an inflamed tissue to exert their effects. Both tumor
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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tissues and inflamed tissues are hypoxic (48) and, by extension,
acidic (49, 50). The ability of cells to function or survive under such
intense environmental stress likely underlies their ability to halt an
ongoing immune response. This appears to be particularly important
in the context of glioma, as we identified via unbiased methods that
arginine metabolism is a central metabolic tenet of TAMCs in
GBM. This comports with a seminal study on the function of arginase-1
myeloid-driven immunosuppression in cancer (51). We found that
not only was the arginase-1 pathway involved in the generation of
ornithine in TAMCs but so was the de novo creatine pathway [via
Glycine amidinotransferase (GATM)], which also generates ornithine. Our results also highlighted that the fate of arginine in TAMCs
is directed toward polyamine generation and not the iNOS pathway,
although myeloid cells are known to use this pathway for immunosuppression in other malignancies (52). One potential explanation is
the preponderance of M-MDSCs in both human and murine models
of glioma (9, 53). As PMN-MDSCs are recognized as the major producer of iNOS-mediated immunosuppression (54), it may be particularly relevant to look at myeloid-polyamine metabolism in the context
of GBM. Why the metabolic phenotype of TAMCs differs so markedly from peripheral myeloid cells is likely a result of predominate
migration and accumulation of MDSC in gliomas (53), intratumoral
proliferation of myeloid cells (55), or cues that come from the TME
(56). How these cues influence metabolic phenotypes is unknown and
an important topic for future exploration. While this study was focused mainly on TAMCs, microglial populations were also affected
by DFMO administration, suggesting that microglia may also play a
role in the inflammatory responses to polyamine blockade.
Our second observation is that the polyamine metabolic pathway
is critical for TAMC-mediated immunosuppression in GBM. The
importance of polyamine anabolism on TAMC function is consistent
with the aforementioned studies on the importance of the polyamine
pathway in the maintenance of M2 myeloid lineage cells. The mechanistic insights into these observations were mainly attributed to
changes in gene expression (29) or epigenetic status of the cells
(45, 46). We did find that DFMO might exert its role by up-regulating
TNF, a proinflammatory cytokine seen up-regulated in ODC conditional KO mice (45). Further work is needed to understand how
polyamine influences inflammatory gene expression.
Our third observation is that blockade of de novo polyamine
generation via DFMO is therapeutically relevant for murine models
of GBM. It is unexpected that monotherapy with DFMO caused increased animal survival in immunocompetent animals, which was
abrogated in the immunodeficient model of the disease (57). As our
data showed that significant survival benefit with DFMO was abrogated in RAG-1 KO mice, this indicates that DFMO functions via
promotion of antitumor adaptive immune responses. This result
highlights the importance of the de novo polyamine pathway on
immunity that is compartmental in nature. The immunologic consequences of polyamine inhibition are still relatively unknown, but
our work shows that myeloid cells are likely the primary target of
such therapy. We saw that treatment with DFMO increased PD-L1
expression in the TME, which has been recently used as an indicator of increased inflammation in glioma (58). For this reason, we
believe that targeting the PD–PD-L1 pathway will further enhance
adaptive immune response by blocking T cell exhaustion (59). We
found that polyamine inhibition can work in concert with T cell–
based immunotherapies for this disease. The mechanisms behind
this combinatorial approach are currently under investigation.
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This occurs because proton/CO2 extrusion is needed to maintain intracellular pH during glycolysis (36–38). This has been recently
shown as a method by which T cells hinder their own effector functions (39). As tumors tend to use extensive glycolytic metabolism,
this may be why atypical proton extruders carbonic anhydrases IX
and XII are up-regulated in solid tumors (40, 41). Therefore, it is possible that polyamines are generated within TAMCs to facilitate intracellular pH normalization and, thus, glycolytic metabolism.
To test this, we generated TAMCs with or without DFMO in vitro,
cultured the cells under decreasing pHs, and performed extracellular
flux analysis using Seahorse analysis (Fig. 6A). Under all conditions
of reducing pH, both control and DFMO pretreated samples had
a significant reduction in ECAR (extracellular acidification rate)
(P < 0.001 for all comparisons within groups at each pH). When comparing across treatments, basal ECAR was reduced in DFMO-treated
TAMCs under all pHe (pH 7.4: 69.1 ± 2 mpH/min in control versus
35.0 ± 3.7 mpH/min in DFMO pretreated; pH 7.0: 51.0 ± 1 mpH/min
in control versus 26.0 ± 0.8 mpH/min in DFMO pretreated; pH 6.7:
30.6 ± 0.7 mpH/min in control versus 20.0 ± 1.3 mpH/min in DFMO
pretreated; P < 0.001). Furthermore, both glucose-stimulated ECAR
and maximal ECAR were significantly reduced by DFMO pretreatment at pH 7.4 and 7.0 (P < 0.001). At pH 6.7, differences between
DFMO and control groups were not observed, suggesting a limitation
to the buffering capacity of polyamines in this system.
Last, to determine whether metabolic perturbation of TAMCs
occurs in the context of glioma, we performed TAMC isolation and
performed 13C-glucose flux analysis from CT-2A tumor–bearing
animals (Fig. 6B). DFMO-pretreated animals had significantly reduced glycolytic metabolism as shown by reduced M+3 pyruvate
(44.6 ± 3.8% in control versus 10.2 ± 4.6% in DFMO treated; P < 0.01)
and lactate incorporation (1.9 ± 0.2% in control versus 1.0 ± 0.13% in
DFMO treated; P < 0.05). Using an in vivo carbon flux model (42), we
assessed 13C-glucose flux in vivo in control and DFMO-treated animals to look at bulk tumor 13C-glucose flux (Fig. 6C). While there was
enhanced M+3 lactate incorporation by the bulk TME compared to
the liver (52.5 ± 2.3% in tumor versus 20.7 ± 3.2% in the liver; P < 0.01),
there was no change in the bulk tumor glycolytic metabolism of DFMO-
treated animals. This final observation highlights the specificity of
DFMO on blunting TAMC immunosuppression in GBM.
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Unfortunately, polyamine inhibition has not yet yielded significant
benefits in the clinic (60). This is similar to clinical experience with
immunotherapies (61), and the reasons for this are currently unknown. Recent work has shown that steroid administration and
standard-of-care therapies, both of which are frequently given to
patients, can potently inhibit antitumor immune responses (62, 63)
and may play a role in treatment resistance, but more work is needed to understand these interactions.
A caveat of these treatment modalities is that they did not elicit
long-term survival benefit. The reasons for this are unknown, but
considering that T cells undergo significant metabolic programming
at different stages of activation/memory (64), it is possible that
de novo polyamine generation is important for an immunological
memory phenotype or some other unknown processes critical for
long-term antitumor immunity. In the future, it will be critical to
uncover when polyamine generation is needed for T cells and why.
Related to this point is that polyamines can be acquired exogenously.
The ability of cells to complement de novo polyamine generation
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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with exogenous uptake has inspired compounds that inhibit polyamine uptake (65). There are currently a number of clinical trials
focused on this combinatorial modality. As the uptake inhibitors have
very limited accessibility to the CNS, future work will be focused on
understanding whether we can deliver this next-generation polyamine
therapeutics to patients with GBM.
Our last observation is that polyamines act as an intracellular pH
buffer that promotes both the survival and metabolic functions of
TAMCs in GBM. Polyamines are incredibly basic compounds, which
were initially discovered as the major constituent of semen (66).
This acidic environment is recapitulated in solid tumors, and our
data show that TAMCs generate their own basic metabolites to survive under these harsh conditions. This phenomenon is not without
precedent, as a previous study showed that polyamine blockade induces intracellular acidification in leukemic cells (67). Many tumors
are known to up-regulate polyamine generation, which is why studies
have argued that polyamines are immunosuppressive compounds
(65, 68). Our data, however, suggest that the presence of polyamines
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Fig. 6. Polyamines promote the metabolism of TAMCs under conditions of pHe. (A) TAMCs were generated in the context of DFMO, and after 6 days of differentiation,
cells were lifted, adhered using Cell-Tak adhesive, and cultured in decreasing pH medium. Immediately following addition of acidic medium, Seahorse extracellular flux
analysis was performed to determine glycolytic metabolism. (B) DFMO-treated animals had TAMCs isolated, and ex vivo 13C-glucose flux was performed. (C) In vivo
13
C-glucose flux was performed by infusion of 13C-glucose (100 mg/ml) over a 2.5-hour period. After infusion, tumor, adjacent parenchyma, and liver were flash-frozen for
bulk metabolite analysis. (A) n = 5 per group, representative of two independent experiments. (B) Each sample is n = 10 mice pooled per sample, with three pooled samples submitted in triplicate; data are representative of two independent experiments. (C) n = 3 mice were individually analyzed per group. Statistics were calculated via
unpaired Student’s t tests: *P < 0.05, **P < 0.01, and ***P < 0.001. 2-DG, 2-deoxyglucose; PEP, phosphoenolpyruvate.
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is actually a survival mechanism for cells. Perhaps endowing T cells
with an enhanced ability to generate their own polyamines may actually
be beneficial for their function in tumors. As both glycolytic and
mitochondrial metabolism generate a large amount of acidic end
products, we have also observed that de novo polyamine generation
also maintains intracellular pH and, thus, metabolic fitness of TAMCs.
Note that whole-tumor glucose flux did not reveal the same changes
induced by DFMO treatment on TAMCs, further highlighting the
specificity of the de novo polyamine pathway on this immunosuppressive subset.
In summation, this work shows that polyamine metabolism is a
central tenet of immunosuppression in GBM that can be targeted
effectively. This lays groundwork for future studies to understand
the exact roles that polyamines have on different glioma-infiltrating
cellular subsets and how we can use them to promote antitumor
immunity for this untreatable disease.

Mouse models
All mice were housed at the Center for Comparative Medicine at
Northwestern Feinberg School of Medicine. Mice are all housed in
a conventional barrier facility with 12-hour light/12-hour dark
cycles and ad libitum access to food and water. C57/Bl6, OT-1 Bl6,
and RAG0/0 Bl6 mice were obtained from The Jackson Laboratory
(Bar Harbor, ME) and bred for use in experiments. All experiments
were performed in mice 6 to 8 weeks old, age- and gender-matched.
Equal numbers of male and female mice were used whenever possible. For all Kaplan-Meier curves, C57/Bl6 mice were purchased at
6 weeks old, and numbers of male/female mice were always equivalent between control and experimental groups. All mouse protocols
performed in this study were approved by Northwestern’s Institutional Animal Care and Use Committee under study approval
number IS00002459.
Cell lines and tumor implantation
The CT-2A tumor line was initially obtained from T. Seyfried (Boston
College). The GL-261 tumor line was purchased from the National
Cancer Institute (NCI). Cells were cultured in Dulbecco’s modified
Eagle’s medium (Corning) supplemented with 10% fetal bovine
serum (FBS; HyClone) and penicillin-streptomycin. For injections,
cells were lifted with trypsin-EDTA (Corning), washed with phosphate-
buffered saline (PBS), and suspended at a concentration of 7.5 × 104 cells
(1.0 × 105 for GL-26 and 2 × 105 for GL-26–OVA) per 2.5 l. Mice
were implanted with CT-2A using a stereotactic apparatus following the exact specifications as described previously (69). Following
this method, tumor cell injection has a 100% engraftment rate in
C57/Bl6 mice. GL-261 lines overexpressing OVA were generated
previously (70) and cultured in G-418 (200 g/ml; Sigma-Aldrich)
to maintain selection pressure.
Tissue and cellular isolations
Mice
Tumor-bearing mice were perfused with 1× PBS before tumors were
removed and homogenized in Hanks’ balanced salt solution (Gibco,
Thermo Fisher Scientific) using a Dounce homogenizer (Sigma-
Aldrich). Homogenized tissues were passed through a 70-m filter,
spun, and then resuspended in 30% Percoll (GE Healthcare) layered
carefully over 70% Percoll solution for density gradient centrifugaMiska et al., Sci. Adv. 2021; 7 : eabc8929
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Magnetic bead isolation of cells
To isolate specific populations of cells, single-cell suspensions as
isolated above are preblocked with anti-CD16/32 for 15 min at
4°C. We then used the biotinylated anti-Gr1 (clone RB6-8C5), anti-
CD8, or anti-CD163 antibodies (all from Thermo Fisher Scientific)
to label murine myeloid, CD8+, and human monocytes, respectively.
Next, the cells were washed and then incubated with anti-biotin
magnetic beads (Miltenyi Biotec) before performing manual positive
selection using MS columns (Miltenyi Biotec). Purified cells were
analyzed for all downstream metabolic analyses.
In vitro T cell/TAMC generation
TAMCs were generated as described previously (9). Briefly, bone
marrow precursors were isolated from the femurs of C57/Bl6 mice
or C57 OT-1 mice and resuspended in RPMI supplemented with
recombinant granulocyte-macrophage colony-stimulating factor (GMCSF) (40 ng/ml) and 50% of 0.2-m sterile-filtered CT-2A supernatant.
After 3 days, cells were washed and replaced with the same medium.
At 6 days, cells were validated to be phenotypically similar to
TAMCS in vivo (9). CD8+ T cells were isolated from the spleens of
mice using a MagniSort CD8+ T cell Enrichment kit (Thermo Fisher
Scientific) and stimulated with mouse T cell–activating Dynabeads
(Thermo Fisher Scientific). For antigen-specific activation, we used
SIINFEKL peptide (50 ng/ml) on OT-1 isolated T cells.
Histological evaluation of tumors
For hematoxylin and eosin (H&E) analysis, tumors were implanted,
and 5 days after tumor implantation, brains were harvested and fixed
overnight in 10% neutral buffered formalin overnight. Samples were
submitted to the Northwestern Pathology Core, where paraffin embedding and H&E staining were performed. Validation of tumor
engraftment was performed by certified neuropathologist. For
immunofluorescence, mice were perfused with 10 ml of PBS, and
brains were snap-frozen in OCT (Sakura Tissue-Tek). Brains were
then cut into 8-m-thick sections using a CM1860 cryostat (Leica,
Wetzlar, Germany). Sections were fixed with 100% methanol prechilled at −80°C for 10 min. Sections were blocked in 5% normal rat
serum for 30 min, washed, and then incubated 1:100 with anti-
CD8–PE (phycoerythrin) and anti-CD11b–Alexa Fluor 488. Last,
sections were mounted using Fluoroshield with DAPI (4′,6-diamidino-
2-phenylindole) (Sigma-Aldrich). Four control and four DFMO-
treated mice were used for analysis, with two independent images
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MATERIALS AND METHODS

tion as performed previously (69). Interface was collected and washed
in PBS before any downstream analysis. For splenic isolation, spleens
were directly homogenized though a 70-m strainer, followed by
red blood lysis using ACK buffer (Gibco, Thermo Fisher Scientific).
Cells were washed and then used for all downstream analysis.
Humans
Fresh tumor tissue was harvested from newly diagnosed GBM
patients, manually diced with a sterile scalpel, and incubated with
collagenase/deoxyribonuclease 1 (DNase 1)/ Tosyl-l-lysyl-chloromethane
hydrochloride (TLCK) (all Sigma-Aldrich) mixture for 15-min intervals
at 37°C. Once tissue was digested, it was homogenized and leukocytes
were isolated via Percoll gradient centrifugation as described for mouse
tumor isolation. For peripheral blood mononuclear cell (PBMC) isolation, blood was isolated from matched patients and leukocytes were
isolated via Ficoll-Paque ® PLUS (GE Healthcare) density gradient centrifugation. PBMCs were washed and used for all downstream analysis.
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analyzed for infiltration per mouse. Image identities were blinded
and counted blindly by A.R.

Extracellular flux assays
Extracellular flux analysis on TAMCs was performed using a Seahorse
XFe96 analyzer (Agilent), as previously described (72). Briefly,
TAMCS were lifted and adhered to microplates using Cell-Tak
Adhesive (Thermo Fisher Scientific) at a density of 1 × 105 cells per
well. Glycolytic flux was measured using the glycolysis stress test
(Agilent) following the manufacturer’s guidelines.
Miska et al., Sci. Adv. 2021; 7 : eabc8929
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Metabolic flux analyses
Arginine flux
SILAC RPMI medium was supplemented with 10% dialyzed FBS
(Fisher), glycine (40 mg/ml), and U 13C-arginine (200 mg/ml;
Cambridge Isotope Laboratories). All cells were washed with blank
SILAC before being reconstituted in 13C medium at a concentration
of 1 × 106 to 2 × 106 cells/ml for 2 to 4 hours, depending on the
assay. Cells were lifted and washed twice with PBS before pellets
were flash-frozen and stored at −80°C until metabolite extraction.
Pellets were resuspended in 80% methanol/20% H2O and then lysed
by 3× cycles of heat shock (LN2 freezing followed by 42°C water bath).
Samples were then spun at 14,000 rpm for 15 min; supernatant was
collected and analyzed as described below.
Glucose flux
Glucose-free RPMI medium was supplemented with 10% dialyzed
FBS and U13C-glucose (2 g/liter; Cambridge Isotope Laboratories).
All cells were washed with blank SILAC before being reconstituted
in 13C medium at a concentration of 1 × 106 to 2 × 106 cells/ml for
2 to 4 hours, depending on the assay. Cells were lifted and washed
twice with PBS before pellets were flash-frozen and stored at −80°C
until metabolite extraction.
In vivo flux
In vivo glucose flux was performed exactly as described previously
(42), adapted to our tumor models. Two weeks after tumor implantation (7 days after DFMO administration), mice were continuously
anesthetized with isoflurane using an anesthetic vaporizer (Harvard
Apparatus) connected to mouse tail illuminator/restrainer (Braintree
Scientific). U13C-Glucose was diluted to 100 mg/ml in 0.9% saline
(Baxter) and loaded into 1-ml Luer-lock syringes (Becton Dickinson).
Loaded tubes were connected via MicroRenathane tubing (Braintree)
to a 27-gauge scalp-vein butterfly needle (Exelint International). Mice
were injected with a 130-l bolus of label, before being infused at a
rate of 2.5 l/min using a syringe pump (Braintree) for 2.5 hours.
After infusion, mice were immediately euthanized and tumor, normal
brain, and liver were flash-frozen in LN2 and stored at −80°C until
extraction. For metabolite extraction, 50 mg of frozen tissue was
homogenized in 3 ml of 80% methanol/20% H2O using a Polytron
homogenizer (Kinematica USA). Homogenized samples were incubated at −80°C overnight and then spun at 14,000 rpm for 15 min;
supernatant was collected and analyzed as described below.
Normalizations for metabolic data
To ensure rigor of data presented, two independent forms of
normalization were performed on all samples. For samples that
involved cellular isolation, we normalized each submission to the
lowest cell count obtained to ensure uniformity in injection. These
numbers of cells submitted to LC-MS/MS were always between 5 × 105
and 2 × 106 cells. For in vivo infusion data, we weighed tissues to
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Immunophenotyping
Single-cell suspensions were blocked with anti-CD16/32 antibodies
before incubation with antibody panels as described below. For cytokine staining, cells were preincubated with phorbol 12-myristate
13-acetate (PMA)/ionomycin + brefeldin A for 4 hours before fixation
and intracellular staining. The Foxp3 fixation/permeabilization
(Invitrogen, Thermo Fisher Scientific) protocol was used for all
intracellular flow cytometric analysis (71).
The following myeloid panel was used for flow cytometric analysis: Live/Dead eFluor 780 (Thermo Fisher Scientific), anti-CD45
BV510, anti-CD3 PE-Cy7, anti-C11b Pacific Blue, anti-Ly6C AF
700, anti-Ly6G peridinin chlorophyll protein (Percp)–cy5.5, anti–
arginase 1 allophycocyanin (APC), anti–PD-L1 PE, anti-CD11c
BV605, anti–TGF-–LAP BV711, and anti–interleukin-10 (IL-10)
fluorescein isothiocyanate (FITC). All antibodies are purchased
from BioLegend except arginase-1 (Thermo Fisher Scientific).
The following flow cytometry panel was used for lymphocytic
analysis: Live/Dead eFluor 780, anti-CD45 BV510, anti-CD4 PECy7, anti-CD8–BV605, anti-CD44 Percpcy5.5, anti-Foxp3 eFluor
450, anti-CD19 BV711, anti-CD25 PE, anti–interferon  (IFN) AF
700, anti-TNF FITC, and anti–granzyme B Alexa Fluor 647. All
antibodies are purchased from BioLegend except Foxp3 (Thermo
Fisher Scientific). This allows us to define conventional T cells
(CD45+CD3+CD4+CD8−Foxp3−), regulatory T cells (CD45+CD3+
CD4+CD8−Foxp3+CD25+), B cells (CD45+CD3−CD19+), and natural
killer (NK) cells (CD45+CD3−NK1.1+). IFN, TNF, and granzyme B
expression are a measure of inflammatory phenotype on each of
these cells.
The following flow cytometry panel was used for tetramer analysis: Live/Dead eFluor 780, anti-CD45 BV510, anti-CD4 PE-Cy7,
anti-CD8 PE (clone KT15 from Medical & Biological Laboratories
Co.), anti-CD44 Percpcy5.5, anti-Foxp3 eFluor 450, anti-CD11b
BV711, and anti–SIINFEKL-H2kb tetramer Alexa Fluor 488. The
conjugated tetramers were generated by the National Institutes of
Health (NIH) Tetramer Facility at Emory University. Tetramer staining was performed at room temperature for 45 min.
For pHrodo Red intracellular pH measurement, cells from spleen
or tumor were counted, normalized, and incubated with 500 nm
pHrodo Red dye in PBS at 37°C for 30 min before being washed
twice with 2% FBS/PBS wash buffer. This step was performed before live/dead and antibody staining as described above.
For cell necrosis/apoptotic measurement, TAMCs were washed
with PBS before being incubated with live/dead eFluor 780 for 30 min
on ice. Cells were washed twice with annexin V binding buffer
(BioLegend) before being incubated with annexin V FITC (1:20;
BioLegend) for 15 min at room temperature. Cells were then washed
twice with annexin binding buffer (Becton Dickinson) and kept in
binding buffer during flow cytometric analysis.

RNA-seq analysis
Fourteen days after CT-2A tumor implantation, 10 mice were pooled
for each n reported in this study, followed by Gr1 magnetic bead
isolation, and RNA was isolated using TRIzol (Thermo Fisher
Scientific)–based RNA purification. Briefly, 0.2 ml of chloroform
was added to TRIzol samples; top RNA-containing layer was precipitated with 70% isopropanol. Pellets were dried, then resuspended
in sterile water, and sent for analysis. Isolated samples were sent to
Novogene, which analyzed RNA for quality and provided all data as
total counts and fpkm (fragments per kilobase per million reads)
values. Fpkm values are reported throughout this manuscript.
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impermeant dye IncuCyte Cytotox Green (Essen Bioscience) was
added at a 1:1000 dilution to monitor for apoptosis. Cells were imaged every 20 min for 4 hours, and fluorescence flux of pHrodo Red
was measured over time. After 2 hours of measurement, nigericin/
valinomycin was added to experimental wells to measure clamped pH.

Hydrophilic metabolite profiling
Isolated TAMC and CD8+ T cells samples were dried using a SpeedVac.
Acetonitrile (50%) was added to the tube for reconstitution following overtaxing for 30 s. Sample solution was then centrifuged for
15 min at 20,000g and 4°C. Supernatant was collected for LC-MS
analysis. Samples were analyzed by high-performance LC (HPLC)
and high-resolution MS and MS/MS (HPLC-MS/MS). The system
consists of Thermo Q Exactive with an electrospray source and an
UltiMate3000 (Thermo Fisher Scientific) series HPLC consisting of
a binary pump, degasser, and autosampler outfitted with an XBridge
Amide column (Waters; dimensions of 4.6 mm by 100 mm and a
3.5-m particle size). The mobile phase A contained 95% water/5%
acetonitrile (v/v), 20 mM ammonium hydroxide, and 20 mM
ammonium acetate (pH 9.0); phase B was 100% acetonitrile. The
gradient was performed as follows: 0 min, 15% A; 2.5 min, 30% A;
7 min, 43% A; 16 min, 62% A; 16.1 to 18 min, 75% A; and 18 to
25 min, 15% A with a flow rate of 400 l/min. The capillary of the
electrospray ionization source was set to 275°C, with sheath gas at
45 arbitrary units, auxiliary gas at 5 arbitrary units, and the spray
voltage at 4.0 kV. In positive/negative polarity switching mode, a
mass/charge ratio (m/z) scan range from 70 to 850 was chosen and
MS1 data were collected at a resolution of 70,000. The automatic
gain control target was set at 1 × 106, and the maximum injection
time was 200 ms. The top five precursor ions were subsequently
fragmented, in a data-dependent manner, using the higher-energy
collisional dissociation cell set to 30% normalized collision energy
in MS2 at a resolution power of 17,500. Data acquisition and analysis were carried out by Xcalibur 4.1 software and TraceFinder 4.1
software, respectively (both from Thermo Fisher Scientific).

Statistical analysis
Statistical significance across two group was determined using twotailed unpaired Student’s t test performed on figures with individual
comparisons. One-way analysis of variance (ANOVA) with Tukey’s
post hoc was performed for comparisons of three or more groups.
Kaplan-Meier curves were generated, and log-rank test was performed
to determine significance of in vivo survival rates. P values were
calculated in Prism software (GraphPad, San Diego, CA), and the
significance is as stated in the figure legends. Error bars are shown
as ±SEMs for all figures. For pHrodo Red analyses, mixed-effects
models for longitudinal data were performed and post hoc analysis
was performed in both R and SAS, which produced similar results.
For MetaboAnalyst data, normalized peak areas were inputted into
online software, and heatmaps were generated based on t test statistical
significance. MetaboAnalyst figure was automatically generated by
the MetaboAnalyst website (74). All statistics were validated by T.X.

pHLIP dye measurement of pHe
Mice were intracranially injected with CT-2A or saline. Fourteen
days after tumor engraftment, 100 l of pHLIP-Cy5.5 dye at 100 M
(synthesized and provided by Y.K.R.) was administered via intravenous
injection. Twenty-four hours after injection, brains and spleens from
both controls and tumor-bearing mice were immediately harvested
and scanned with a spectral Lago (Spectral Imaging Systems,
Tucson, AZ) with excitation at 675 nm and emission at 730 nm. The
fluorescence intensities in regions of interest were calculated using
Aura Imaging Software.
IncuCyte time-based fluorescence assay
TAMCs were generated and treated with inhibitors DFMO as described above. At day 6, cells were labeled with pHrodo Red AM,
and the same number of cells (1 × 106 cells) was labeled with the
same concentration of dye before being washed for IncuCyte analysis. TAMCs were resuspended at a concentration of 1 × 105/ml in
live cell imaging buffer (Thermo Fisher Scientific) at a pH of 7.4,
7.0, and 6.7. To generate a pH standard curve, TAMCs were pretreated with pH 7.4, 7.0, and 6.7 solution containing nigericin/
valinomycin to clamp intracellular pH to extracellular pH. The fluorescence measurement of these standards was used to generate a curve
by which the experimental groups were measured. The membrane-
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SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/8/eabc8929/DC1
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